Skip to content
Screener

Organon OGN Ganirelix Acetate Injection — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Cumberland Pharmaceuticals logo
CPIXAcetadote — Revenue
$136.66K-29.4%
Proto Labs logo
PRLBInjection Molding — Revenue
$51.07M+4.8%
KLA Corp. logo
KLACWafer Inspection — Revenue
$1.78B+0.5%
Artesian Resources logo
ARTNAInspection Fees — Revenue
$134K-21.6%
TIC Solutions logo
TICInspection & Mitigation — Revenue
$296.7M-5.5%
Lennar logo
LENOther revenues — Revenue
$331.4M-6.8%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.56B+57.0%
Enterprise value$11.01B+4.2%
P/E6.6×+2.1×
P/S0.6×+0.2×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Organon’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 8:46 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-029532
($ in millions)Three Months Ended March 31, 2025 / U.S.2025 / Int’lTotalU.S.Int’lTotal
Nexplanon/Implanon NXT$127$74$201$176$72$248
Follistim AQ213961353469
NuvaRing6182461622
Ganirelix Acetate Injection2242652327
Marvelon/Mercilon—2626—3939
Jada5—515—15
Other Women’s Health (1)173046152743
General Medicines

Item 1. Financial Statements (unaudited)

FAQ

What is Organon's ganirelix acetate injection — revenue?
Organon (OGN) reported ganirelix acetate injection — revenue of $26M in Q1 2026.
How has Organon's ganirelix acetate injection — revenue changed year-over-year?
Organon's ganirelix acetate injection — revenue decreased by 3.7% year-over-year, from $27M to $26M.
What is the long-term trend for Organon's ganirelix acetate injection — revenue?
Over 3 years (2021 to 2025), Organon's ganirelix acetate injection — revenue has grown at a -3.4% compound annual growth rate (CAGR), from $111M to $100M.
What does ganirelix acetate injection — revenue mean?
This metric represents the total gross or net revenue generated from the sale of Ganirelix Acetate Injection, a specialized pharmaceutical product. It reflects the market demand and commercial performance of this specific therapeutic offering within the company's broader portfolio. Tracking this revenue helps investors assess the product's lifecycle stage and its contribution to the company's overall top-line growth.

Ask your AI about Organon's ganirelix acetate injection — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude